Brain serotonin neurotoxicity and primary pulmonary hypertension from fenfluramine and dexfenfluramine: A systematic review of the evidence

JAMA

Volumn 278, Issue 8, 1997, Pages 666-672

  McCann, Una D ^a   Seiden, Lewis S ^b   Rubin, Lewis J ^c   Ricaurte, George A ^d  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; 5 HYDROXYINDOLEACETIC ACID; 5,6 DIHYDROXYTRYPTAMINE; 5,7 DIHYDROXYTRYPTAMINE; AMINOREX; AMPHETAMINE; ANOREXIGENIC AGENT; ANTIBODY; ANTICOAGULANT AGENT; CHLORAMPHETAMINE; DEXFENFLURAMINE; DIURETIC AGENT; FENFLURAMINE; GLIAL FIBRILLARY ACIDIC PROTEIN; NEUROMODULIN; OXYGEN; PHENTERMINE; POTASSIUM; PROSTACYCLIN; SEROTONIN; SEROTONIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR; STRUCTURAL PROTEIN; TRICYCLIC ANTIDEPRESSANT AGENT; TRYPTOPHAN HYDROXYLASE; VASODILATOR AGENT;

BODY MASS; BRAIN; CLINICAL FEATURE; DOSE RESPONSE; DRUG BRAIN LEVEL; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; HUMAN; IMMUNOHISTOCHEMISTRY; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; NEUROTOXICITY; NONHUMAN; OBESITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; SEROTONINERGIC NERVE CELL; SUBCUTANEOUS DRUG ADMINISTRATION; TRANSPLANTATION;

EID: 0030867864     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.278.8.666     Document Type: Review

References (107)

1. National Task Force on the Prevention and Treatment of Obesity. Long-term pharmacotherapy in the management of obesity. JAMA. 1996;276: 1907-1915.
2. Weintraub M, Sundaresan PR, Madan M, et al. Long-term weight control study, I (weeks 0 to 34): the enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo. Clin Pharmacol Ther 1992; 51:586-594.
3. Weintraub M, Sundaresan PR, Schuster B, et al. Long-term weight control study, II (weeks 34 to 104): an open-label study of continuous fenfluramine plus phentermine versus targeted intermittent medication as adjuncts to behavior modification, caloric restriction, and exercise. Clin Pharmacol Ther 1992;51:595-601.
4. Weintraub M, Sundaresan PR, Schuster B, Moscucci M, Stein EC. Long-term weight control study, III (weeks 104 to 156): an open-label study of dose adjustment of fenfluramine and phentermine. Clin Pharmacol Ther. 1992;51:602-607.
5. Weintraub M, Sundaresan PR, Schuster B, et al. Long-term weight control study, IV (weeks 156 to 190): the second double-blind phase. Clin Pharmacol Ther. 1992;51:608-614.
6. Weintraub M, Sundaresan PR, Schuster B, Averbuch M, Stein EC, Byrne L. Long-term weight control study, V (weeks 190 to 210): follow-up of participants after cessation of medication. Clin Pharmacol Ther. 1992;51:615-618.
7. Weintraub M, Sundaresan PR, Cox C. Long-term weight control study, VI: individual participant response patterns. Clin Pharmacol Ther. 1992;51:619-633.
8. Weintraub M, Sundaresan PR, Schuster B. Long-term weight control study, VII (weeks 0 to 210): serum lipid changes. Clin Pharmacol Ther 1992;51:634-641.
9. Weintraub M. Long-term weight control study: conclusions. Clin Pharmacol Ther. 1992;51:642-646.
10. Food and Drug Administration, Endocrinologic and Metabolic Drugs Advisory Committee. Transcript of September 28, 1995; 1995:345-349.
11. Food and Drug Administration, Endocrinologic and Metabolic Drugs Advisory Committee. Transcript of November 16, 1995; 1995:1-298.
12. Rubin LJ. Primary pulmonary hypertension. N Engl J Med. 1997;336:111-117.
13. Sanders-Bush E, Bushing JA, Sulser F. Long-term effects of p-chloroamphetamine and related drugs on the central serotonergic mechanisms. J Pharmacol Exp Ther. 1975;192:33-41.
14. Harvey JA, McMaster SE. Fenfluramine: evidence for a neurotoxic action and a long-term depletion of brain serotonin. Commun Psychopharmacol. 1975;1:217-228.
15. Clineschmidt BV, Totaro JA, McGuffin JC, et al. Fenfluramine: long-term reduction in brain serotonin (5-hydroxytryptamine). Eur J Pharmacol. 1976; 35:211-214.
16. Harvey JA, McMaster SE, Fuller RW. Comparison between the neurotoxic and serotonin-depleting effects of various halogenated amphetamine derivatives in the rat. J Pharmacol Exp Ther 1977; 202:581-589.
17. Fuller RW, Snoddy HD, Hemrick SK. Effects of fenfluramine and norfenfluramine on brain serotonin metabolism in rats. Proc Soc Exp Biol Med. 1978; 157:202-205.
18. Clineschmidt BV, Zacchei AG, Totaro JA, et al. Fenfluramine and brain serotonin. Ann N Y Acad Sci. 1978;305:222-241.
19. Steranka LR, Sanders-Bush E. Long-term effect of fenfluramine on central serotonergic mechanisms. Neuropharmacology. 1979;19:895-903.
20. Bjorklund A, Nobin A, Stenevi U. Effects of 5,6-dihydroxytryptamine on nerve terminal serotonin and serotonin uptake in the rat brain. Brain Res. 1973;53:117-127.
21. Baumgarten HG, Bjorklund A, Lachenmayer L, Nobin A, Stenevi U. Long-lasting depletion of brain serotonin by 5,7-dihydroxytryptamine. Acta Physiol Scand. 1971;373:3-14.
22. Schuster CR, Lewis M, Seiden LS. Fenfluramine: neurotoxicity. Psychopharmacol Bull 1986; 22:148-151.
23. Rowland NE. Effect of continuous infusions of dexfenfluramine on food intake, body weight, and brain amines in rats. Life Sci. 1986;39:2581-2586.
24. Kleven MS, Schuster CR, Seiden LS. Effect of depletion of brain serotonin by repeated fenfluramine on neurochemical and anorectic effects of acute fenfluramine. J Pharmacol Exp Ther. 1988; 246:822-828.
25. Kleven MS, Seiden LS. d-, 1-, dl-Fenfluramine cause long lasting depletions of serotonin in rat brain. Brain Res. 1989;505:351-353.
26. Johnson MP, Nichols DE. Comparative serotonin neurotoxicity of the stereoisomers of fenfluramine and norfenfluramine. Pharmacol Biochem Behav. 1990;36:105-109.
27. Zaczek R, Battaglia G, Culp S, Appel N, Contrera J, De Souza E. Effects of repeated fenfluramine administration on indices of monoamine function in rat brain: pharmacokinetic, dose-response, regional specificity, and time-course data. J Pharmacol Exp Ther. 1990;253:104-112.
28. Caccia S, Anelli M, Ferrarese A, et al. The role of d-norfenfluramine in the indole-depleting effect of fenfluramine. Eur J Pharmacol. 1993;233:71-77.
29. Colado MI, Murray TK, Green AR. 5-HT loss in rat brain following 3,4-methylenedioxymethamphetamine (MDMA), p-chloroamphetamine and fenfluramine administration and effects of chlormethiazole and dizocilpine. Br J Pharmacol. 1993;108:583-589.
30. Westphalen RI, Dodd PR. New evidence for a loss of serotonergic nerve terminals in rats treated with d,l-fenfluramine. Pharmacol Toxicol 1993;72: 249-255.
31. Westphalen RI, Dodd PR. The nature of d,l-fenfluramine induced 5-HT re-uptake transporter loss in rats. Mol Neurobiol. 1995;11:165-175.
32. Mennini T, Gobbi M, Crespi D, et al. In vivo and in vitro interaction of flunarazine with d-fenfluramine serotonergic effects. Pharmacol Biochem Behav. 1996;53:155-161.
33. Appel NM, Contrera JF, De Souza EB. Fenfluramine selectively and differentially decreases the density of serotonergic nerve terminals in the rat brain: evidence from immunocytochemical studies. J Pharmacol Exp Ther. 1989;249:928-943.
34. Molliver DC, Molliver ME. Anatomic evidence for a neurotoxic effect of (±)-fenfluramine upon serotonergic projections in the rat. Brain Res. 1990; 511:165-168.
35. Sotelo C. Immunohistochemical study of short-and long-term effects of d,l-fenfluramine on the serotonergic innervation of the rat hippocampal formation. Brain Res. 1991;541:309-326.
36. Appel NM, Mitchell WM, Contrera JF, DeSouza EB. Effects of high-dose fenfluramine treatment on monoamine uptake sites in rat brain: assessment using quantitative autoradiography. Synapse. 1990; 6:33-44.
37. Wilson MA, Molliver ME. Microglial response to degeneration of serotonergic axon terminals Glia. 1994;11:18-34.
38. Rowland NE, Kalehua AN, Li B, Semple-Rowland SL, Streit WJ. Loss of serotonin uptake sites and immunoreactivity in rat cortex after dexfenfluramine occur without parallel glial cell reactions. Brain Res. 1993;624:35-43.
39. O'Callaghan JP, Miller DB. Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mouse. J Pharmacol Exp Ther. 1994;270:741-751.
40. Rose S, Hunt S, Collins P, Hindmarsh J, Jenner P. Repeated administration of escalating doses of dexfenfluramine does not produce morphological evidence of neurotoxicity in the cortex of rats. Neurodegeneration. 1996;5:145-152.
41. Kalia M. Reversible, short-lasting, and dose-dependent effect of (+)fenfluramine on neocortical serotonergic axons. Brain Res. 1991;548:111-125.
42. Caccia S, Sarati S, Anelli M, Garattini S. Effect of escalating doses of d-fenfluramine on the content of indoles in brain. Neuropharmacoloqy. 1992;31: 875-879.
43. Clemens JA, Fuller RW, Perry KW, Sawyer BD. Effects of p-chloro-amphetamine on brain serotonin in immature rats. Commun Psychopharmacol. 1978;2:11-16.
44. Lucot JB, Wagner GC, Schuster CR, Seiden LS. Decreased sensitivity of rat pups to long-lasting dopamine and serotonin depletions produced by methylamphetamine. Brain Res. 1982;247:181-183.
45. Steranka L, Sanders-Bush E. Species differences in the rate of disappearance of fenfluramine and its effects on brain serotonin neurons. Biochem Pharmacol. 1979;28:3103-3107.
46. McCann U, Hatzidimitriou G, Ridenour A, et al. Dexfenfluramine and serotonin neurotoxicity: further preclinical evidence that clinical caution is indicated. J Pharmacol Exp Ther. 1994;269:792-798.
47. Rowland NE. Long-term administration of dexfenfluramine to genetically obese (ob/ob) and lean mice: body weight and brain serotonin changes. Pharmacol Biochem Behav. 1994;49:287-294.
48. Baumann MH, Schuster CR, Rothman RB. Effects of phentermine and cocaine on fenfluramine-induced depletion of serotonin in mouse brain. Drug Alcohol Depend. 1996;41:71-74.
49. Fracaso C, Guiso G, Confalonieri S, Bergami A, Garattini S, Caccia S. Depletion and time-course of recovery of brain serotonin after repeated subcutaneous dexfenfluramine in the mouse: a comparison with the rat. Neuropharmacology. 1995;34:1653-1659.
50. Rowland NE, Carlton J. Neurobiology of an anorectic drug: fenfluramine. Prog Neurobiol. 1986; 27:13-62.
51. Gerfen CR. The neostriatal mosaic, I: compartmental organization of projections from the striaturn to the substantia nigra in the rat. J Comp Neurol. 1985;236:454-476.
52. Ricaurte GA, Molliver ME, Martello MB, et al. Dexfenfluramine neurotoxicity in brains of non-human primates. Lancet. 1991;338:1487-1488.
53. Scheffel S, Szabo Z, Matthews W, Dannals R, Ravert H, Ricaurte GA. Fenfluramine-induced loss of serotonin transporters in baboon brain visualized with PET. Synapse. 1996;24:395-398.
54. Harwood PD. Therapeutic dosage in small and large mammals. Science. 1963;139:684-685.
55. Mordenti J, Chappell W. The use of interspecies scaling in toxicokinetics. In: Yacobi A, Kelly J, Batra V, eds. Toxicokinetics in New Drug Development. Elmsford, NY: Pergamon Press Inc; 1989:42-96.
56. Chappell W, Mordenti J. Extrapolation of toxicological and pharmacological data from animals to humans. In: Testa B, ed. Advances in Drug Research. San Diego, Calif: Academic Press Inc; 1991: 1-116.
57. Marchant NC, Breen MA, Wallace D, et al. Comparative biodisposition and metabolism of 14C-(+/-)-fenfluramine in mouse, rat, dog and man. Xenobiotica. 1992;22:1251-1266.
58. Caccia S, Ballabio GG, Guiso G, et al. Species differences in the kinetics and metabolism of fenfluramine isomers. Arch Int Pharmacodyn Ther. 1982;258:15-28.
59. Marchant NC, Bass S, Breen MA, et al. Species differences in the metabolism of [14C]-dl,fenfluramine. Prog Pharmacol Clin Pharmacol 1991;8:23-30.
60. McTavish D, Heel RC. Dexfenfluramine: a review of its pharmacological properties and therapeutic potential in obesity. Drugs. 1992;43:713-733.
61. Westphalen RI, Dodd PR. The regeneration of d,l-fenfluramine-destroyed serotonergic nerve terminals. Eur J Pharmacol. 1993;238:399-402.
62. Laferrere B, Wurtman RJ. Effect of d-fenfluramine on serotonin release in brains of anaesthetized rats. Brain Res. 1989;504:258-263.
63. Axt KJ, Mamounas LA, Molliver ME. Structural features of amphetamine neurotoxicity in the brain. In: Cho A, Segal D, eds. Amphetamine and Its Analogs: Neuropsychopharmacology, Toxicology and Abuse. San Diego, Calif: Academic Press Inc; 1994:315-367.
64. Fischer C, Hatzidimitriou G, Wlos J, Katz J, Ricaurte G. Reorganization of ascending 5-HT axon projections in animals previously exposed to the recreational drug 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy'). J Neurosci. 1995;15: 5476-5485.
65. Pinder R, Brogden R, Sawyer R, Speight T, Avery G. Fenfluramine: a review of its pharmacological properties and therapeutic efficacy in obesity. Drugs. 1975;10:241-323.
66. Fuxe K, Hamberger B, Farnebo L, Ogren S. On the in vivo and in vitro actions of fenfluramine and its derivatives on central monoamine neurons, especially 5-hydroxytryptamine neurons, and their relation to the anorectic activity of fenfluramine. Postgrad Med J. 1975;51:35-45.
67. Carlton J, Rowland NE. Anorexia and brain serotonin: development of tolerance to the effects of fenfluramine and quipazine in rats with serotonin-depleting lesions. Pharmacol Biochem Behav 1984; 20:739-745.
68. Schechter MD. Functional consequences of fenfluramine neurotoxicity. Pharmacol Biochem Behav. 1990;37:623-626.
69. Ricaurte GA, Sabol KE, Seiden LS. Functional consequences of toxic amphetamine analog exposure. In: Cho A, Segal D, eds. Amphetamine and Its Analogs: Neuropsychopharrnacology, Toxicology and Abuse. San Diego, Calif: Academic Press Inc; 1994:297-309.
70. Caccia S, Anelli M, Ferrarese A, Fracasso C, Garatinni S. Single-and multiple-dose kinetics of d-fenfluramine in rats given anorectic and toxic doses. Xenobiotica. 1992;22:217-226.
71. Guy-Grand BJP, Crepaldi G, Lefebvre P, et al. International trial of long-term dexfenfluramine in obesity. Lancet. 1989;2:42-1145.
72. Finnegan KT, Ricaurte GA, Davis-Richie L, Irwin I, Peroutka SP, Langston JW. Orally administered 3,4-methylenedioxymethamphetamine causes a long-term depletion of serotonin in rat brain. Brain Res. 1988;447:141-144.
73. Ricaurte GA, DeLanney LE, Irwin I, Langston JW. Toxic effects of 3,4-methylenedioxymethamphetamine on central serotonergic neurons in the primate: importance of route and frequency of drug administration. Brain Res. 1988;446:165-168.
74. Baumgarten G, Garattini S, Lorens S, Wurtman R. Dexfenfluramine and neurotoxicity. Lancet 1992;339:359, 360-361.
75. Kalia M. Dexfenfluramine and neurotoxicity Lancet. 1992;339:360.
76. Coccaro EF, Murphy DL. Serotonin in Major Psychiatric Disorders. Washington, DC: American Psychiatric Press; 1990.
77. Sandler M, Coppen A, Harnett S, eds. 5-Hydroxytryptamine in Psychiatry: A Spectrum of Ideas. Oxford, United Kingdom: Oxford University Press Inc; 1991.
78. Derome-Tremblay M, Nathan C. Fenfluramine studies. Science. 1989;43:1989.
79. Oswald I, Lewis SA, Dunleary DLF, Brezinova V, Briggs M. Drugs of dependence though not of abuse: fenfluramine and imipramine. BMJ 1971;3: 70-73.
80. Steel JM, Briggs M. Withdrawal depression in obese patients after fenfluramine treatment. BMJ. 1972;3:26-27.
81. Lewis SA, Oswald I, Dunleavy DLF. Chronic fenfluramine administration: some cerebral effects. BMJ. 1971;3:67-70.
82. Hording T. Depression following fenfluramine withdrawal. Br J Psychiatry. 1972;121:338-339.
83. Myers JE, Mieczkowski T, Perel J, Abbondanza D, Cooper TB, Mann JJ. Abnormal behavioral responses to fenfluramine in patients with affective and personality disorders: correlation with increased serotonergic responsivity. Biol Psychiatry. 1994;35:112-120.
84. Marshall BDJ, Glynn SM, Midha KK, et al. Adverse effects of fenfluramine in treatment refractory schizophrenia. J Clin Psychopharmacol. 1989; 9:110-115.
85. Myers J, Buysse D, Thase M, et al. The effects of fenfluramine on sleep and prolactin in depressed patients: a comparison of potential indices of brain serotonergic responsivity. Biol Psychiatry. 1993;34-753-758.
86. Rubin LJ. Primary pulmonary hypertension. Chest. 1993;104:236-250.
87. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med. 1991;115:343-349.
88. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension: a national prospective study. Ann Intern Med. 1987;107:216-223.
89. Rich S, Kaufmann E, Levy PS. The effect of high dose of calcium-channel blockers on the survival of primary pulmonary hypertension. N Engl J Med. 1992;327:76-81.
90. Fuster V, Steele PM, Edwards WD, et al. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation. 1984;70: 580-587.
91. Pasque MK, Trulock EP, Kaiser LR, Cooper JD. Single-lung transplantation for pulmonary hypertension. Circulation. 1991;84:2275-2279.
92. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacy clin) with conventional therapy for primary pulmonary hypertension. New Engl J Med. 1996;334:296-301.
93. Higenbottam TW, Spiegelhalter D, Scott JP, et al. Prostacyclin (epoprostenol) and heart-lung transplantation as treatments for severe pulmonary hypertension. Br Heart J. 1993;70:366-370.
94. Gurtner HP. Aminorex and pulmonary hypertension. Cor Vasa. 1985;27:160-171.
95. Brenot F, Herve P, Petitpretz P, Parent F, Duroux P, Simonneau G. Primary pulmonary hypertension and fenfluramine use. Br Heart J. 1993; 70:537-541.
96. McMurray J, Bloomfield P, Miller HC. Irreversible pulmonary hypertension after treatment with fenfluramine. BMJ. 1986;293:51-52.
97. Pouwels HM, Smeets JL, Cheriex EC, Wouters EF. Pulmonary hypertension and fenfluramine. Eur Respir J. 1990;3:606-607.
98. Loogen F, Worth H, Schwan G, et al. Long-term follow-up of pulmonary hypertension in patients with and without anorectic drug intake. Cor Vasa. 1985;27:111-124.
99. Nall KC, Rubin LJ, Lipskind S, Sennesh JD. Reversible pulmonary hypertension associated with anorexigen use. Am. J Med. 1991;91:97-99.
100. Abenhaim L, Moride Y, Brenot F, et al, for the International Primary Pulmonary Hypertension Study Group. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med. 1996;335:609-616.
101. International Primary Pulmonary Hypertension Group. Final report on suspected risk factors, International Primary Pulmonary Hypertension Study. Submitted to the Food and Drug Administration, July 26, 1996.
102. Weir EK, Reeve HL, Huang JMC, et al. The anorexic agents aminorex, fenfluramine, and dexfenfluramine inhibit potassium current in pulmonary vascular smooth muscle and cause pulmonary vasoconstriction. Circulation. 1996;94:2216-2220.
103. Yuan XJ, Aldinger AM, Orens JB, Conte JV, Rubin LJ. Dysfunctional voltage-gated potassium channels in the pulmonary artery smooth muscle cells of patients with primary pulmonary hypertension. Circulation. 1996;94:1-48.
104. Herve P, Launey JM, Scrobohaci ML, et al. Increased plasma serotonin in primary pulmonary hypertension. Am J Med. 1995;99:249-254.
105. Kuczmarski R, Flegal K, Campbell S, Johnson C. Increasing prevalence of overweight among US adults. JAMA. 1994;272:205-211.
106. Atkinson RL, Hubbard VS. Report on the NIH Workshop on Pharmacologic Treatment of Obesity. Am J Clin Nutr. 1994;60:153-156.
107. Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med. In press.